Skip to main content
. Author manuscript; available in PMC: 2017 Nov 21.
Published in final edited form as: JCO Precis Oncol. 2017 Oct 30;2017:10.1200/PO.17.00127. doi: 10.1200/PO.17.00127

Table 4.

PSA50 Response Rate to Next-Line Therapy Based on Change in Clinical Practice After AR-V7 Testing

Management Did the Patient Achieve a PSA50 Response on Next-Line Therapy?
Yes No
n/N % n/N %
Changed 34/63 53.97 29/63 46.03
Did not change 16/52 30.77 36/52 69.23

NOTE. Fisher’s exact test P = .015.

Abbreviations: AR-V7, androgen receptor splice variant 7; n/N, number of patients in that category divided by total number of patients; PSA50, 50% decline in prostate-specific antigen.